The Bioinformatics Analysis of miRNAs Signatures Differentially Expressed in HER2(+) Versus HER2(-) Breast Cancers

被引:3
|
作者
Nie, Weiwei [1 ]
Jin, Lei [2 ]
Wang, Yanru [1 ]
Wang, Zexing [3 ]
Guan, Xiaoxiang [1 ,3 ]
机构
[1] So Med Univ, Jinling Hosp, Sch Med, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[2] Nanjing Univ, Jinling Hosp, Sch Med, Dept Stomatol, Nanjing 210002, Jiangsu, Peoples R China
[3] Nanjing Univ, Jinling Hosp, Sch Med, Dept Med Oncol, Nanjing 210002, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
bioinformatics; breast cancer; HER2; miRNAs; MICRORNAS;
D O I
10.1089/cbr.2012.1311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To identify the signatures of miRNAs differentially expressed in HER2(+) versus HER2(-) breast cancers that accurately predict the HER2 status of breast cancer, and to provide further insight into breast cancer therapy. Methods: By the methods of literature search, aberrant expressed miRNAs were collected. By target prediction algorithm of TargetScan and PicTar and the data enrichment analysis, target gene sets of miRNAs differentially expressed in HER2(+) versus HER2(-) breast cancers were built. Then, using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) database, the function modules of Gene Ontology categories and Kyoto Encyclopedia of Genes and Genomes (KEGG) and BIOCARTA pathway, biological functions and signaling pathways that are probably regulated by miRNAs, were analyzed. Results: We got five sets of miRNAs expressed in different HER2 status of breast cancers finally. The five sets of data contain 22; 32; 3; 38; and 62 miRNAs, respectively. After miRNAs target prediction and data enrichment, 5,734; 22,409; 1,142; 22,293; and 43,460 target genes of five miRNA sets were collected. Gene ontology analysis found these genes may be involved in transcription, protein transport, angiogenesis, and apoptosis. Moreover, certain KEGG and BIOCARTA signaling pathways related toHER2 status were found. Conclusion: Using TargetScan and PicTar for data enrichment, and DAVID database, Gene Ontology categories, KEGG and BIOCARTA pathway for analysis of miRNAs different expression, we conducted a new method for biological interpretation of miRNA profiling data in HER2(+) versus HER2(-) breast cancers. It may improve understanding the regulatory roles of miRNAs in different molecular subtypes of breast cancers. Therefore, it is beneficial to improve the accuracy of experimental efforts to breast cancer and potential therapeutic targets.
引用
收藏
页码:71 / 76
页数:6
相关论文
共 50 条
  • [1] HER2 Intermediate Breast Cancers
    Jensen, Kristin C.
    Nielsen, Torsten O.
    Gilks, C. Blake
    West, Robert B.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (11) : 1739 - 1739
  • [2] HER2 0, HER2 1+and HER2 2+/FISH Negative Breast Cancers Are Biologically Different
    Mon, Khin Su
    Zhang, Hui
    Aragao, Alessa
    Tang, Ping
    LABORATORY INVESTIGATION, 2023, 103 (03) : S182 - S183
  • [3] HER2 0, HER2 1+and HER2 2+/FISH Negative Primary Breast Cancers Are Biologically Distinct
    Donahue, Nolan
    Aragao, Alessa
    Gordezky, Rachel
    Haddad, Sandra
    Tang, Ping
    LABORATORY INVESTIGATION, 2024, 104 (03) : S146 - S148
  • [4] Activating HER2 mutations in HER2 gene amplification negative breast cancers.
    Bose, R.
    Kavuri, S. M.
    Searleman, A. C.
    Shen, W.
    Shen, D.
    Koboldt, D. C.
    Monsey, J.
    Li, S.
    Ding, L.
    Mardis, E. R.
    Ellis, M. J.
    CANCER RESEARCH, 2012, 72
  • [5] HER2 Positive Breast Cancers with Progression
    Solanki, Malvika
    Chitambar, Christopher
    Jorns, Julie
    LABORATORY INVESTIGATION, 2019, 99
  • [6] HER2 Positive Breast Cancers with Progression
    Solanki, Malvika
    Chitambar, Christopher
    Jorns, Julie
    MODERN PATHOLOGY, 2019, 32
  • [7] Oligonucleotide Array Analysis of the HER2 Amplicon in Breast Cancers
    Lytvak, I.
    Gunn, S. R.
    Yeh, I.
    MODERN PATHOLOGY, 2010, 23 : 61A - 61A
  • [8] Oligonucleotide Array Analysis of the HER2 Amplicon in Breast Cancers
    Lytvak, I.
    Gunn, S. R.
    Yeh, I.
    LABORATORY INVESTIGATION, 2010, 90 : 61A - 61A
  • [9] HER2 or not HER2: That is the question
    Burstein, HJ
    Winer, EP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 3656 - 3659
  • [10] A Comparative Analysis of the Value of Her2 Immunohistochemistry Scoring in Primary and Metastatic Breast Cancer, in the Era of Her2 "LOW" Breast Cancers
    Bhardwaj, Swati
    Kandel, Avi
    Collins, Victoria
    Zeizafoun, Nebras
    Zeng, Jennifer
    Jaffer, Shabnam
    LABORATORY INVESTIGATION, 2023, 103 (03) : S103 - S103